(ENZ) Enzo Biochem - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2941001024
ENZ: Proteins, Antibodies, Peptides, Small Molecules, Reagents, Kits
Enzo Biochem Inc (NYSE:ENZ) is a life sciences company specializing in the development and marketing of innovative labeling and detection technologies for biological targets. Founded in 1976 and headquartered in Farmingdale, New York, the company serves a diverse customer base including academic researchers, clinical researchers, biotechnology firms, pharmaceutical companies, and diagnostic manufacturers. Its product portfolio includes labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins, which are integral to drug discovery, translational research, and drug development processes. Enzo Biochem’s technologies are utilized in various research areas such as cell biology, genomics, immunohistochemistry, and small molecule chemistry. The company also licenses its proprietary technologies to enhance research and development efforts in the life sciences industry.
Enzo Biochem’s products and services are designed to enable precise and efficient analysis in drug development and research. The company’s genomic probes and immunoassays are particularly valuable in identifying and quantifying biological targets, facilitating advancements in personalized medicine and therapeutic interventions. By providing tools for labeling, detecting, and visualizing biological targets, Enzo Biochem plays a critical role in accelerating the transition from basic research to clinical applications. Its focus on innovation and precision has established it as a trusted partner in the global life sciences industry.
Based on the provided
Additional Sources for ENZ Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
ENZ Stock Overview
Market Cap in USD | 26m |
Sector | Healthcare |
Industry | Diagnostics & Research |
GiC Sub-Industry | Health Care Services |
IPO / Inception | 1980-06-12 |
ENZ Stock Ratings
Growth 5y | -80.7% |
Fundamental | -66.7% |
Dividend | 36.7% |
Rel. Strength Industry | -57.1 |
Analysts | - |
Fair Price Momentum | 0.43 USD |
Fair Price DCF | - |
ENZ Dividends
Dividend Yield 12m | 13.16% |
Yield on Cost 5y | 5.24% |
Annual Growth 5y | -100.00% |
Payout Consistency | 100.0% |
ENZ Growth Ratios
Growth Correlation 3m | -97.1% |
Growth Correlation 12m | -58.5% |
Growth Correlation 5y | -77.8% |
CAGR 5y | -23.53% |
CAGR/Max DD 5y | -0.27 |
Sharpe Ratio 12m | -0.08 |
Alpha | -67.31 |
Beta | 0.98 |
Volatility | 46.80% |
Current Volume | 38.2k |
Average Volume 20d | 97.2k |
As of March 15, 2025, the stock is trading at USD 0.50 with a total of 38,239 shares traded.
Over the past week, the price has changed by +7.20%, over one month by -8.75%, over three months by -50.75% and over the past year by -56.73%.
No, based on ValueRay Fundamental Analyses, Enzo Biochem (NYSE:ENZ) is currently (March 2025) a stock to sell. It has a ValueRay Fundamental Rating of -66.72 and therefor a negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of ENZ as of March 2025 is 0.43. This means that ENZ is currently overvalued and has a potential downside of -14%.
Enzo Biochem has no consensus analysts rating.
According to ValueRays Forecast Model, ENZ Enzo Biochem will be worth about 0.5 in March 2026. The stock is currently trading at 0.50. This means that the stock has a potential downside of -2%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 5.5 | 1000% |
Analysts Target Price | 5.5 | 1000% |
ValueRay Target Price | 0.5 | -2% |